Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...
Enrollment complete in the replicate REDUCE 1 and REDUCE 2 Phase 3 studies with pivotal data expected in Q2 2026 SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage ...
SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 ...
Gout patients frequently have a number of comorbidities, including obesity, hypertension, high serum lipid and cholesterol levels, kidney disease, diabetes, and cardiovascular disease. [2,7,19–21] Due ...
Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition. The Chinese biotech evaluated the oral ...
Although these lesions are typically a late feature of gout, gouty tophi occasionally present early in the course of disease, either as the initial manifestation of gout or within a few years of first ...
Hosted on MSN
Crystalys Therapeutics launches with $205 million funding round for trials of gout drug
(Reuters) -Crystalys Therapeutics said on Tuesday it has emerged from stealth mode with a funding round of $205 million to help finance global late-stage trials of its lead drug as a treatment for ...
kidney cross section Researchers assessed the incidence and potential risk factors for the development of fenofibrate-associated nephrotoxicity in patients with gout. Fenofibrate-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback